# Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)

> **NCT00135473** · PHASE3 · COMPLETED · sponsor: **SepNet - Critical Care Trials Group** · enrollment: 600 (—)

## Conditions studied

- Severe Sepsis
- Septic Shock

## Interventions

- **DRUG:** 10% Hemohes® (10% Hydroxyethyl starch)
- **DRUG:** Sterofundin® (Ringer lactate solution)
- **DRUG:** Actrapid® (Insulin)

## Key facts

- **NCT ID:** NCT00135473
- **Lead sponsor:** SepNet - Critical Care Trials Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 600 (—)
- **Last updated:** 2016-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135473, "Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00135473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*